High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The S&P 500 and Nasdaq regain their 50-day lines and Treasury yields fall in a bullish day two Fed reaction. SpaceX, AMD, Moderna are buys.
Dow Jones futures: Despite Friday's bounce, the stock market had a tough week amid $100 oil prices and surging Treasury yields. Apple, Moderna are buys.
Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma.
Three catalysts, one reshuffling, and a Fed that refuses to move
Moderna Stock Jumps as Wolfe Upgrade Puts Cancer Pipeline in Spotlight
Plus, the secret’s out on the Catskills, and Democrats gear up for a wave of investigations into Trump and his allies.
Michael Reinking, Senior Market Strategist at the NYSE, recaps a week dominated by Treasury Secretary Bessent, whose doubled liquidity support buybacks reignited the debasement trade, sending gold back above 4,500 and triggering a massive crypto short squeeze that propelled Bitcoin up ~15% and Ethereum up 25%. Escalating Iran tensions pushed ICE Brent into the low 90s after a 60-day ceasefire expired, while equity markets drifted lower with the S&P 500 down ~1.5% as retail earnings disappointed broadly and healthcare surged nearly 4% on landmark cancer trial results from Merck and Moderna. Looking ahead, next week's PCE print, Nvidia earnings, and Fed Chair Warsh's first Jackson Hole speech are the marquee events to watch.
A new mRNA cancer vaccine hit its goal in melanoma patients, giving a healthcare giant a fresh growth story.
Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.
CHICAGO, Aug 19 () - Merck and Moderna's success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which revs up the immune system, personalized cancer vaccines train the immune system to specifically target mutations found only on a person's tumor.
1. Moderna shares more than doubled after it reported successful results in an experimental mRNA-based cancer vaccine. The company and its partner Merck reported this morning that the vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients. The positive results sent Moderna’s share price soaring and rippled through drug industry stocks as investors saw the potential for more future blockbusters.
Investors rotated toward profitable drugmakers while personalized cancer-vaccine results energized biotechnology stocks.
The result could reshape Moderna's post-vaccine growth story
On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.
By Julie Steenhuysen and Christy Santhosh CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of melanoma recurrence and spread in a late-
Shares of US vaccine-maker Moderna soared 60 per cent in pre-market trading after the company reported successful results for a melanoma cancer...
President Donald Trump discussed efforts to de-escalate US-Iran tensions with Qatari Emir Tamim bin Hamad Al Thani.
Moderna Inc (MRNA) exceeds Q2 revenue guidance and advances key vaccines, but faces delays in norovirus trial and oncology readouts.
Moderna (MRNA) delivered earnings and revenue surprises of 0.00% and +14.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Moderna posted a narrower per-share loss and higher revenue in its latest quarter, but shares were tumbling anyway. Moderna posted a loss of $1.97 a share, narrower than the loss of $2.01 Wall Street had anticipated, and slimmer than the per-share loss of $2.13 reported last year. The drugmaker reiterated its full-year guidance of 10% revenue growth, evenly split between U.S. and international sales.
Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 2.1% year on year to $145 million. Its GAAP loss of $1.97 per share was 4.2% above analysts’ consensus estimates.
Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
